SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has been dosed with 64Cu SAR-bisPSMA in the dosimetry phase of the SECuRE clinical trial (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate resistant prostate cancer (mCRPC) at the Urology Cancer Center and GU Research Network in Omaha, Nebraska.
Clarity's Executive Chairman, Dr Alan Taylor, commented, "We are very excited to have treated our first US patient in the SECuRE trial for mCRPC using our optimised PSMA agent, 64/67Cu SAR-bisPSMA, and look forward to recruiting additional patients and opening all seven clinical sites selected for this trial in the US. We believe the central manufacture, logistical and treatment advantages of TCTs using copper-64 and copper-67 in large patient populations such as prostate cancer will benefit both clinicians and patients.
The SECuRE trial is a Phase I/IIa theranostic trial for identification and treatment of PSMA-expressing mCRPC using TCT. 64Cu SAR-bisPSMA is used to image and select patients for 67Cu SAR-bisPSMA therapy. The initial dosimetry phase utilises 64Cu SAR-bisPSMA to determine biodistribution and dosimetry over multiple time points. The entire trial is a multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients in the US. The aim of this trial is to determine the safety and efficacy of 67Cu-SAR-bisPSMA as a therapy.
Dr Luke Nordquist, CEO, Urologic Medical Oncologist at the Urology Cancer Center and GU Research Network in Omaha, Nebraska, who treated the first patient with 64Cu SAR-bisPSMA in the trial, commented on this milestone, "64/67Cu SAR-bisPSMA products hold great promise of improving prostate cancer diagnosis and treatment and have the potential to provide significant supply benefits in comparison to current products in the market. We look forward to working together with Clarity to explore these benefits and utilise them to improve the lives of men with this insidious disease."
Dr Taylor said: "The prostate cancer market is a key focus for Clarity. The news of the SECuRE trial recruitment milestone comes shortly after treating our first patient in the PROPELLER trial, a diagnostic 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer (NCT04839367)[2]. We are excited to now have two clinical trials in prostate cancer actively recruiting and treating patients and to build on the compelling results from our therapeutic and diagnostic preclinical studies. We look forward to progressing these trials and getting closer to achieving our ultimate goal of developing better treatments for children and adults with cancer."
About Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide[3]. In 2021, the National Cancer Institute estimated 248,530 new cases of prostate cancer in the US and around 34,130 deaths from the disease[4]. Annually, there are around ~34,000 men in the US who are diagnosed with mCRCP[5], ~90% of whom have tumours which express PSMA[6].
References
[1]. ClinicalTrials.gov Identifier: NCT04868604 https://clinicaltrials.gov/ct2/show/NCT04868604
[2]. ClinicalTrials.gov Identifier: NCT04839367 https://clinicaltrials.gov/ct2/show/NCT04839367
[3]. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
[4]. American Cancer Society, Cancer Statistics Center,
https://cancerstatisticscenter.cancer.org/?_ga=2.79808020.284532473.1620009137-1916069442.1615761164#!/cancer-site/Prostate
[5]. American Cancer Society, Cancer Statistics Center,
https://cancerstatisticscenter.cancer.org/?_ga=2.79808020.284532473.1620009137-1916069442.1615761164#!/cancer-site/Prostate
[6]. D. A. Silver, I. Pellicer, W. R. Fair, W. D. Heston and C. Cordon-Cardo 1997. "Prostate-specific membrane antigen expression in normal and malignant human tissues." Clinical Cancer Research. vol. 3, 81-85, January 1997
This announcement has been authorised for release by the Board.
About Clarity Pharmaceuticals
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
www.claritypharmaceuticals.com/
View original content:https://www.prnewswire.com/news-releases/first-patient-treated-in-claritys-cu-64cu-67-sar-bispsma-theranostic-prostate-cancer-trial-301362306.html
![Figure 1. Images show considerable reduction in lesion uptake (64Cu-SAR-bisPSMA PET) following 4 doses of 67Cu-SAR-bisPSMA (4GBq each; PET conducted in July 2024, approximately 14 months post-fourth cycle). Reduction in uptake (maximum standardised uptake value [SUVmax]) and tumour volume: 72.5% and 41.6%, respectively. New bone lesions identified (red circles) in the most recent image prior to the fifth dose. The fifth dose was delivered on 30 July 2024, with PSA having fallen 47.5% as of 24 September 2024 and trending downward. Post-treatment scans are pending.](https://mma.prnasia.com/media2/2531886/Images_show_considerable_reduction_lesion_uptake__64Cu_SAR_bisPSMA_PET__4_doses.jpg?p=medium600)
